Myeloproliferative Neoplasms (MPN)

INCA33989 Shows Disease-Modifying Potential With Favorable Safety in Essential Thrombocythemia: John Mascarenhas, MD

Phase 1 Trials Assess Safety, Dosing of CAL-R Antibody for Essential Thrombocythemia: John Mascarenhas, MD

Rusfertide Offers Sustainable PV Management Strategy: Andrew Kuykendall, MD

Fatigue, Quality of Life Improve With Rusfertide: Andrew Kuykendall, MD

Rusfertide Cuts Phlebotomy Need in Polycythemia Vera: Andrew Kuykendall, MD

Reducing Polycythemia Vera–Associated Thrombotic Risk Through Iron Regulation

Understanding Hematocrit Thresholds in Polycythemia Vera Treatment

Managing Polycythemia Vera to Reduce Risks and Improve Lives

The Challenge of Managing Both Disease Symptoms and Drug Side Effects in Myelofibrosis

Options for MPN Treatment Are Expanding Rapidly With More on the Horizon